Synopsis of areas of uncertainty in BsAb research and relative specific challenges
| Areas of uncertainty . | Challenges . |
|---|---|
| Management of T-cell overactivation syndromes | Identifying risk factors for CRS |
| Optimal step-up dosing, drug formulation, prophylaxis | |
| Outpatient administration | |
| Patient and provider education | |
| DOR | Optimal duration of BsAb therapy |
| Predictors of durable response | |
| Moving BsAb to earlier lines of therapy | Competitive landscape |
| Selecting the most appropriate patient populations (eg, high-risk disease) | |
| Optimal combinations | Moving beyond cytotoxic agents as partners |
| Rational (rather than expedient) combinations | |
| Understanding mechanisms of resistance | Identifying actionable tumor-intrinsic resistance mechanisms |
| Detailed characterization of T-cell function (and dysfunction) during BsAb therapy | |
| Dissecting the role of other players in the lymphoma immune microenvironment |
| Areas of uncertainty . | Challenges . |
|---|---|
| Management of T-cell overactivation syndromes | Identifying risk factors for CRS |
| Optimal step-up dosing, drug formulation, prophylaxis | |
| Outpatient administration | |
| Patient and provider education | |
| DOR | Optimal duration of BsAb therapy |
| Predictors of durable response | |
| Moving BsAb to earlier lines of therapy | Competitive landscape |
| Selecting the most appropriate patient populations (eg, high-risk disease) | |
| Optimal combinations | Moving beyond cytotoxic agents as partners |
| Rational (rather than expedient) combinations | |
| Understanding mechanisms of resistance | Identifying actionable tumor-intrinsic resistance mechanisms |
| Detailed characterization of T-cell function (and dysfunction) during BsAb therapy | |
| Dissecting the role of other players in the lymphoma immune microenvironment |